Kidney cancer affects over 80,000 Americans annually, with renal cell carcinoma as the dominant type. Benjamin R. Lee, MD, MBA, outlines current AUA guideline recommendations, including when to…
Dr. Allison Betof Warner from Stanford University joins Rahul Gosain, MD and Rohit Gosain, MD, on the Oncology Brothers podcast to discuss melanoma treatment. The conversation covers the…
NEW YORK (Reuters Health) – A multicenter center study has shown that adding cetuximab to neoadjuvant chemotherapy and preoperative radiotherapy improves overall survival after excision of high-risk rectal…
NEW YORK (Reuters Health) – A multicenter center study has shown that adding cetuximab to neoadjuvant chemotherapy and preoperative radiotherapy improves overall survival after excision of high-risk rectal…
NEW YORK (Reuters Health) – In general, adding pemetrexed to cisplatin therapy does not improve overall survival (OS) in patients with recurrent or metastatic head and neck cancer,…
NEW YORK (Reuters Health) – Disease-free survival is not improved after resection of stage III colon cancer when cetuximab is added to chemotherapy with leucovorin, fluorouracil, and oxaliplatin…
NEW YORK (Reuters Health) – A guideline issued by the American Society of Clinical Oncology recommends that actual rather than an adjusted ideal body weight should be used…
NEW YORK (Reuters Health) – Reduced-dose chemotherapy in children with Down syndrome (DS) associated acute myeloid leukemia or myelodysplastic syndrome effectively maintains survival, researchers report in a March…
NEW YORK (Reuters Health) – In a European study, patients at high risk of recurrent gastrointestinal stromal tumor (GIST) who received imatinib (Gleevec; Novartis) for three years after…
NEW YORK (Reuters Health) – The addition of bevacizumab (Avastin; Genentech/Roche) to the standard docetaxel and prednisone in men with progressive metastatic castration-resistant prostate cancer (mCRPC) did not…
NEW YORK (Reuters Health) – The 2009 influenza A(H1N1) pandemic caused severe illness and mortality in cancer patients with solid tumors, investigators report in Cancer online February 22.…
NEW YORK (Reuters Health) – The 20-year survival rate for people diagnosed with thin or T1 melanomas 1 mm thick or less, the most common type, is 96%,…
